Overview

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Status:
Completed

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Eli Lilly and Company

Treatments:

Exenatide